ClinicalTrials.gg
CompletedNCT05363553TIGERUpdated Sep 19, 2024

Transition to Infant Formula Feeding on Gastrointestinal Regurgitation (TIGER) Study

An interventional study of Infant formula based on whole goat milk and infant formula based on cow milk proteins in Gastrointestinal Disorder, Functional, Regurgitation, Gastric and Colic, Infantile, sponsored by Dairy Goat Co-operative (N.Z.) Limited. Completed at 1 site in Thailand. Open to participants aged 2 Weeks to 4 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Dairy Goat Co-operative (N.Z.) Limited · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
2 Weeks to 4 Months
Sex
All
01

Study summary

To compare the frequency of regurgitation and other digestive outcomes between infants who receive an infant formula based on whole goat milk and an infant formula based on cow milk proteins during the transition period from breastfeeding to formula feeding, using predominantly breastfed infants as a reference group.

Read the detailed description

The study is a randomized, double-blind, parallel-group trial to study the effect of feeding infants goat milk or cow milk formula in the first 6 months of life on the prevalence of functional gastrointestinal disorders and other health outcomes, including gastrointestinal health and sleep during the transition from breastfeeding to formula-feeding. A predominantly breastfed group is used as a reference group.

02

Conditions studied

  • Gastrointestinal Disorder, Functional
  • Regurgitation, Gastric
  • Colic, Infantile
  • Constipation - Functional
  • Infant Development

Keywords

  • infant formula
  • goat milk
  • regurgitation
03

In context

Gastrointestinal Diseases

548 studies on the registry are indexed under Gastrointestinal Diseases; 101 are open to participants now.

This study's enrollment of 146 is above the median of 80 across 388 interventional studies indexed under Gastrointestinal Diseases.

Browse Gastrointestinal Diseases studies →

Lead sponsor

Dairy Goat Co-operative (N.Z.) Limited is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Weeks to 4 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy full-term born infants (≥ 37 weeks + 0 days and \< 41 weeks + 6 days of gestation)
  • birth weight ≥ 2.5 kg and ≤ 4.5 kg
  • born from a singleton pregnancy
  • live in Bangkok or nearby with no plan for geographical migration before 6 months of age
  • for experimental and active comparator groups only: parent(s) has expressed the intention to partially (in combination with breastfeeding) or fully formula-feed the infant and ready to enroll in the study before the age of 4 months/120 days
  • for no intervention group only: parent(s) has expressed the intention to predominantly breastfeed (according to study definition) and ready to enroll in the study before the age of 4 months/120 days
  • infant has been predominantly breastfed for at least 2 weeks before enrollment
  • parent(s) has sufficient Thai language skills to understand the study information, the , and to comply with the study procedure
  • parent(s) is willing and deemed able to fulfil the requirements of the study protocol and procedures
  • at least one parent is of legal age of consent

Exclusion criteria

Exclusion Criteria:

  • infant has any disorder considered to interfere with nutrition, growth or development of the immune system
  • participation of the infant in any other interventional trial or participation of the mother in any intervention trial with infant follow-up
  • for experimental and active comparator groups only: infant has been formula-fed for more than 1 week before enrolment
  • for experimental and active comparator groups only: cow milk allergy or intolerance of the infant
  • for experimental and active comparator groups only: enrolled infant who never consumed any study product until the first visit 2 weeks following enrolment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    infant formula based on whole goat milk

    Dietary Supplement: Infant formula based on whole goat milk

  • Active comparator
    Infant formula based on cow milk proteins

    Dietary Supplement: infant formula based on cow milk proteins

  • No intervention
    Predominantly breastmilk

Interventions

  • Dietary supplementInfant formula based on whole goat milk

    Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months

  • Dietary supplementinfant formula based on cow milk proteins

    Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months

06

What researchers measure

Primary outcomes

  1. Change in daily frequency of regurgitation during the transition period from breastfeeding to formula feeding

    Parental diary record of number of regurgitation per day reviewed at Day 0, Day 14 and Day 28

    Time frame: From Day 0 to Day 28

Secondary outcomes

  1. Frequency of infant regurgitation

    Rome IV criteria diagnosed by physician

    Time frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks

  2. Frequency of infant colic

    Rome IV criteria diagnosed by physician

    Time frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks

  3. Frequency of functional constipation

    Rome IV criteria diagnosed by physician

    Time frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks

  4. Stool consistency

    Stool consistency based on Brussels infants and toddler stool scale (BITSS)

    Time frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks

  5. Stool frequency

    Number of defecations per day

    Time frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks

  6. Feeding difficulties

    NeoEAT questionnaire

    Time frame: Day 0, Day 14, Day 28, and Age 8, 16 and 24 weeks

  7. Sleep

    Brief Infant Sleep questionnaire

    Time frame: Day 0, Day 28, and Age 12 and 24 weeks

  8. Biochemical and metabolic markers: saliva markers

    Saliva: inflammation markers (including enzymes reported in U/mL)

    Time frame: Day 0 and Day 14

  9. Biochemical and metabolic markers: saliva markers

    Saliva: stress markers (including hormones reported in ng/mL)

    Time frame: Day 0 and Day 14

  10. Biochemical and metabolic markers: saliva markers

    Saliva: inflammation markers (including proteins reported in µg/mL)

    Time frame: Day 0 and Day 14

07

Study locations

1 site
  • Pediatric Nutrition Research Unit, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital
    Bangkok, Thailand
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Apr 2024, 23 months.

Of 149 interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2022
First posted
May 6, 2022
StartActual
May 25, 2022
Primary completionActual
Apr 30, 2024
CompletionActual
Aug 28, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05363553
Lead sponsor
Dairy Goat Co-operative (N.Z.) Limited
Responsible party
Sponsor
First posted
May 6, 2022
Start date
May 25, 2022
Primary completion
Apr 30, 2024
Completion
Aug 28, 2024
Last update
Sep 19, 2024

Study contacts

Sirinuch Chomtho, MD, PhD
principal investigator · Chulalongkorn University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion